The P132H mutation of SARS-CoV-2 NSP5 relieves its inhibition on interferon-β activation via blocking MAVS degradation

Yuxin Zhang(Xidian University), Ye Qiu, Shuofeng Yuan(University of Hong Kong - Shenzhen Hospital), Hailan Yao(Capital Institute of Pediatrics), Tong-Yun Wang(Chinese University of Hong Kong), Xing‐Yi Ge(Hunan University), Zhong-Hao Lian(Hunan University), Huihui Yan(Hunan University)

Cellular and Molecular Life Sciences

July 30, 2025

10.1007/s00018-025-05822-6

Cited by 1

Related Papers

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

|The Lancet|2020|9.6k

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

|Emerging Microbes & Infections|2020|3.3k

Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility

|Clinical Infectious Diseases|2020|1.2k

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

|Nature|2020|856

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study

|The Lancet Microbe|2020|838